The role of estrogen receptor-β in breast cancer

Seminars in Reproductive Medicine

Volumn 30, Issue 1, 2012, Pages 5-13

  Murphy, Leigh C ^a   Leygue, Etienne ^a  

^a CANCERCARE MANITOBA   (Canada)

Author keywords

biomarker; breast cancer; endocrine therapy; estrogen receptor ; isoforms; resistance

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; ESTROGEN ACTIVITY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY GLANDS, HUMAN; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856294079     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0031-1299592     Document Type: Article

References (100)

1. Speirs V, Skliris G, Burdall S, Carder P. Distinct expression patterns of ERa and ERb in normal human mammary gland. J Clin Pathol: 2002; 255 371 374 (Pubitemid 34494177)
2. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res: 1997; 57 22 4987 4991 (Pubitemid 27498105)
3. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev: 1999; 20 3 358 417 (Pubitemid 30654784)
4. Frster C, Mkela S, Wrri A., et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci U S A: 2002; 99 24 15578 15583
5. Antal MC, Krust A, Chambon P, Mark M. Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERbeta-null mutant. Proc Natl Acad Sci U S A: 2008; 105 7 2433 2438 (Pubitemid 351520531)
6. Nilsson S, Mkel S, Treuter E., et al. Mechanisms of estrogen action. Physiol Rev: 2001; 81 4 1535 1565 (Pubitemid 32951806)
7. Dotzlaw H, Leygue E, Watson PH, Murphy LC. Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab: 1997; 82 7 2371 2374 (Pubitemid 27287615)
8. Enmark E, Pelto-Huikko M, Grandien K., et al. Human estrogen receptor -gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab: 1997; 82 12 4258 4265 (Pubitemid 27525550)
9. Fuqua SA, Schiff R, Parra I., et al. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res: 1999; 59 21 5425 5428 (Pubitemid 29526449)
10. Jrvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol: 2000; 156 1 29 35 (Pubitemid 30644435)
11. Fox EM, Davis RJ, Shupnik MA. ERbeta in breast canceronlooker, passive player, or active protector? Steroids: 2008; 73 11 1039 1051
12. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer: 2006; 95 5 616 626 (Pubitemid 44325902)
13. Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S, Spelsberg TC. Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol: 2005; 19 6 1555 1568 (Pubitemid 41002985)
14. Weitsman GE, Skliris G, Ung K., et al. Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res Treat: 2006; 100 1 23 31
15. Murphy LC, Watson PH. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer: 2006; 13 2 327 334 (Pubitemid 43886661)
16. Chi A, Chen X, Chirala M, Younes M. Differential expression of estrogen receptor beta isoforms in human breast cancer tissue. Anticancer Res: 2003; 23 1A 211 216 (Pubitemid 36358520)
17. Saji S, Omoto Y, Shimizu C., et al. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res: 2002; 62 17 4849 4853 (Pubitemid 34984402)
18. Shaaban AM, Green AR, Karthik S., et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res: 2008; 14 16 5228 5235
19. Yan M, Rayoo M, Takano EA, Fox SB.; kConFab Investigators. Nuclear and cytoplasmic expressions of ER1 and ER2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res Treat: 2011; 126 2 395 405
20. Moore JT, McKee DD, Slentz-Kesler K., et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun: 1998; 247 1 75 78 (Pubitemid 28412528)
21. Savinov AY, Remacle AG, Golubkov VS., et al. Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res: 2006; 66 5 2716 2724
22. Sanchez M, Picard N, Sauv K, Tremblay A. Challenging estrogen receptor beta with phosphorylation. Trends Endocrinol Metab: 2010; 21 2 104 110
23. Hamilton-Burke W, Coleman L, Cummings M., et al. Phosphorylation of estrogen receptor beta at serine 105 is associated with good prognosis in breast cancer. Am J Pathol: 2010; 177 3 1079 1086
24. Roger P, Sahla ME, Mkel S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res: 2001; 61 6 2537 2541 (Pubitemid 32685835)
25. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Muoz A, Mor G. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol: 2000; 96 3 417 421
26. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res: 2000; 60 2 245 248 (Pubitemid 30070743)
27. Leav I, Lau KM, Adams JY., et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol: 2001; 159 1 79 92 (Pubitemid 33704195)
28. Zhu X, Leav I, Leung YK., et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol: 2004; 164 6 2003 2012 (Pubitemid 38669349)
29. Al-Nakhle H, Burns PA, Cummings M., et al. Estrogen receptor beta1 expression is regulated by miR-92 in breast cancer. Cancer Res: 2010; 70 11 4778 4784
30. Smith L, Brannan RA, Hanby AM., et al. Differential regulation of estrogen receptor beta isoforms by 5 untranslated regions in cancer. J Cell Mol Med: 2009;; July 28 (Epub ahead of print)
31. Murphy LC, Peng B, Lewis A., et al. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol: 2005; 34 2 553 566 (Pubitemid 40585201)
32. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen signaling via estrogen receptor beta. J Biol Chem: 2010; 285 51 39575 39579
33. Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology: 2006; 147 10 4831 4842 (Pubitemid 44402189)
34. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res: 2004; 64 1 423 428 (Pubitemid 38114127)
35. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology: 2001; 142 9 4120 4130 (Pubitemid 32802685)
36. Tonetti DA, Rubenstein R, DeLeon M., et al. Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol: 2003; 87 1 47 55 (Pubitemid 37421338)
37. Hou YF, Yuan ST, Li HC., et al. ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene: 2004; 23 34 5799 5806
38. Warner M, Gustafsson JA. The role of estrogen receptor beta (ERbeta) in malignant diseasesa new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun: 2010; 396 1 63 66
39. Rousseau C, Nichol JN, Pettersson F, Couture MC, Miller WH Jr. ERbeta sensitizes breast cancer cells to retinoic acid: evidence of transcriptional crosstalk. Mol Cancer Res: 2004; 2 9 523 531 (Pubitemid 39281734)
40. Helguero LA, Faulds MH, Gustafsson JA, Haldosn LA. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene: 2005; 24 44 6605 6616 (Pubitemid 41486791)
41. Cheng G, Weihua Z, Warner M, Gustafsson JA. Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland. Proc Natl Acad Sci U S A: 2004; 101 11 3739 3746 (Pubitemid 38386631)
42. Skliris GP, Lewis A, Emberley E., et al. Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer. Breast Cancer Res Treat: 2007; 104 1 75 85 (Pubitemid 46976631)
43. ONeill PA, Davies MP, Shaaban AM., et al. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer: 2004; 91 9 1694 1702 (Pubitemid 39546143)
44. Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci U S A: 2006; 103 35 13162 13167 (Pubitemid 44338933)
45. Peng B, Lu B, Leygue E, Murphy LC. Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol: 2003; 30 1 13 29 (Pubitemid 36305253)
46. Inoue S, Ogawa S, Horie K., et al. An estrogen receptor beta isoform that lacks exon 5 has dominant negative activity on both ERalpha and ERbeta. Biochem Biophys Res Commun: 2000; 279 3 814 819 (Pubitemid 32042861)
47. Zhao C, Matthews J, Tujague M., et al. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res: 2007; 67 8 3955 3962 (Pubitemid 46762185)
48. Tateishi Y, Sonoo R, Sekiya Y., et al. Turning off estrogen receptor beta-mediated transcription requires estrogen-dependent receptor proteolysis. Mol Cell Biol: 2006; 26 21 7966 7976 (Pubitemid 44630996)
49. Bhat RA, Harnish DC, Stevis PE, Lyttle CR, Komm BS. A novel human estrogen receptor beta: identification and functional analysis of additional N-terminal amino acids. J Steroid Biochem Mol Biol: 1998; 67 3 233 240 (Pubitemid 28547092)
50. Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene: 2006; 25 51 6887 6899 (Pubitemid 44657858)
51. Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC. Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol: 2008; 180 1 630 636
52. Harris HA, Albert LM, Leathurby Y., et al. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology: 2003; 144 10 4241 4249 (Pubitemid 37204818)
53. Skliris GP, Munot K, Bell SM., et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol: 2003; 201 2 213 220 (Pubitemid 37258932)
54. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, Warner M, Gustafsson JA, Rochefort H. Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res: 2005; 11 9 3170 3174 (Pubitemid 40637201)
55. Omoto Y, Kobayashi S, Inoue S., et al. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer: 2002; 38 3 380 386 (Pubitemid 34123315)
56. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res: 1999; 59 6 1175 1179 (Pubitemid 29136241)
57. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res: 1998; 58 15 3197 3201 (Pubitemid 28371051)
58. Brett D, Pospisil H, Valcrcel J, Reich J, Bork P. Alternative splicing and genome complexity. Nat Genet: 2002; 30 1 29 30
59. Lemischka IR, Pritsker M. Alternative splicing increases complexity of stem cell transcriptome. Cell Cycle: 2006; 5 4 347 351
60. Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet: 2002; 30 1 13 19
61. Roberts GC, Smith CW. Alternative splicing: combinatorial output from the genome. Curr Opin Chem Biol: 2002; 6 3 375 383 (Pubitemid 34522065)
62. Wessagowit V, Nalla VK, Rogan PK, McGrath JA. Normal and abnormal mechanisms of gene splicing and relevance to inherited skin diseases. J Dermatol Sci: 2005; 40 2 73 84 (Pubitemid 41446205)
63. Gallo JM, Jin P, Thornton CA., et al. The role of RNA and RNA processing in neurodegeneration. J Neurosci: 2005; 25 45 10372 10375 (Pubitemid 41628440)
64. Lee CJ, Irizarry K. Alternative splicing in the nervous system: an emerging source of diversity and regulation. Biol Psychiatry: 2003; 54 8 771 776 (Pubitemid 37205128)
65. Hall PA, Russell SH. New perspectives on neoplasia and the RNA world. Hematol Oncol: 2005; 23 2 49 53 (Pubitemid 41774985)
66. Kalnina Z, Zayakin P, Silina K, Lin A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer: 2005; 42 4 342 357 (Pubitemid 40271278)
67. Cummings M, Iremonger J, Green CA, Shaaban AM, Speirs V. Gene expression of ERbeta isoforms in laser microdissected human breast cancers: implications for gene expression analyses. Cell Oncol: 2009; 31 6 467 473
68. Honma N, Horii R, Iwase T., et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol: 2008; 26 22 3727 3734
69. Gruvberger-Saal SK, Bendahl PO, Saal LH., et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res: 2007; 13 7 1987 1994 (Pubitemid 46649864)
70. Palmieri C, Lam EW, Mansi J., et al. The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res: 2004; 10 7 2421 2428 (Pubitemid 38445702)
71. Miller WR, Anderson TJ, Dixon JM, Saunders PT. Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br J Cancer: 2006; 94 9 1333 1338
72. Sugiura H, Toyama T, Hara Y., et al. Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol: 2007; 37 11 820 828 (Pubitemid 350259000)
73. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A., et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res: 2004; 10 17 5769 5776 (Pubitemid 39180954)
74. Yamashita H, Takahashi S, Ito Y., et al. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci: 2009; 100 11 2028 2033
75. Motomura K, Ishitobi M, Komoike Y., et al. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology: 2010; 79 1-2 55 61
76. Novelli F, Milella M, Melucci E., et al. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res: 2008; 10 5 R74
77. Perou CM, Srlie T, Eisen MB., et al. Molecular portraits of human breast tumours. Nature: 2000; 406 6797 747 752
78. Wu X, Subramaniam M, Grygo SB., et al. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res: 2011; 13 2 R27
79. Jensen EV, Cheng G, Palmieri C., et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A: 2001; 98 26 15197 15202 (Pubitemid 34019150)
80. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol: 2003; 21 10 1973 1979 (Pubitemid 46606386)
81. Foekens JA, van Putten WL, Portengen H., et al. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol: 1993; 11 5 899 908 (Pubitemid 23146085)
82. Zhao C, Gao H, Liu Y., et al. Genome-wide mapping of estrogen receptor-beta-binding regions reveals extensive cross-talk with transcription factor activator protein-1. Cancer Res: 2010; 70 12 5174 5183
83. Grober OM, Mutarelli M, Giurato G., et al. Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics: 2011; 12 36
84. Secreto FJ, Monroe DG, Dutta S, Ingle JN, Spelsberg TC. Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells. J Cell Biochem: 2007; 101 5 1125 1147 (Pubitemid 47253715)
85. Bierie B, Moses HL. Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle: 2009; 8 20 3319 3327
86. Horvath LG, Henshall SM, Lee C-S., et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res: 2001; 61 14 5331 5335 (Pubitemid 32694904)
87. Williams C, Edvardsson K, Lewandowski SA, Strm A, Gustafsson JA. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene: 2008; 27 7 1019 1032 (Pubitemid 351225390)
88. Charn TH, Liu ET, Chang EC, Lee YK, Katzenellenbogen JA, Katzenellenbogen BS. Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Mol Endocrinol: 2010; 24 1 47 59
89. Carder PJ, Murphy CE, Dervan P., et al. A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue. Breast Cancer Res Treat: 2005; 92 3 287 293 (Pubitemid 41279638)
90. Mann S, Laucirica R, Carlson N., et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol: 2001; 32 1 113 118 (Pubitemid 32150637)
91. Murphy LC, Leygue E, Niu Y, Snell L, Ho S-M, Watson PH. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer: 2002; 87 12 1411 1416 (Pubitemid 36044316)
92. Omoto Y, Inoue S, Ogawa S., et al. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett: 2001; 163 2 207 212 (Pubitemid 32126367)
93. Iwase H, Zhang Z, Omoto Y., et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol: 2003; 52 Suppl 1 S34 S38 (Pubitemid 37047022)
94. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res: 2004; 10 22 7490 7499 (Pubitemid 39557510)
95. Fleming FJ, Hill AD, McDermott EW, OHiggins NJ, Young LS. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab: 2004; 89 1 375 383 (Pubitemid 38183907)
96. Myers E, Fleming FJ, Crotty TB., et al. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br J Cancer: 2004; 91 9 1687 1693 (Pubitemid 39546142)
97. Nakopoulou L, Lazaris AC, Panayotopoulou EG., et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol: 2004; 57 5 523 528 (Pubitemid 38655949)
98. Saji S, Omoto Y, Shimizu C., et al. Clinical impact of assay of estrogen receptor beta cx in breast cancer. Breast Cancer: 2002; 9 4 303 307
99. Vinayagam R, Sibson DR, Holcombe C, Aachi V, Davies MP. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancera retrospective study. BMC Cancer: 2007; 7 131
100. Maehle BO, Collett K, Tretli S, Akslen LA, Grotmol T. Estrogen receptor betaan independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? APMIS: 2009; 117 9 644 650